Furthermore, in vivo efficacy study indicated that trastuzumab did not inhibit tumor growth in xenografts expressing the ZNF207-ERBB2 fusion; this finding supported the resistant mechanism to trastuzumab (21). This evidence concerns the gene ZNF207 and neoplasm.